Research graph
References from Pirfenidone exerts anti-inflammatory effects by inhibiting CXCL6 to alleviate idiopathic pulmonary fibrosis. Local targets link to admitted publications; unresolved targets remain external evidence.
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline
10.1164/rccm.202202-0399st · 2022 · External reference
Interstitial lung diseases
10.1016/s0140-6736(22)01052-2 · 2022 · External reference
Pathogenic mechanisms underlying idiopathic pulmonary fibrosis
10.1146/annurev-pathol-042320-030240 · 2022 · External reference
Efficacy and safety of Nintedanib in idiopathic pulmonary fibrosis
10.1056/nejmoa1402584 · 2014 · External reference
Precision medicine advances in idiopathic pulmonary fibrosis
10.1016/j.ebiom.2023.104766 · 2023 · External reference
Pirfenidone in idiopathic pulmonary fibrosis: hitting two birds with one stone?
10.1183/13993003.02224-2024 · 2025 · External reference
Idiopathic pulmonary fibrosis: the inflammation hypothesis revisited
10.1378/chest.124.4.1187 · 2003 · External reference
Histological signatures map anti-fibrotic factors in mouse and human lungs
10.1038/s41586-025-08727-3 · 2025 · External reference
The chemokine system as a key regulator of pulmonary fibrosis: converging pathways in human idiopathic pulmonary fibrosis (IPF) and the bleomycin-induced lung fibrosis model in mice
10.3390/cells13242058 · 2024 · External reference
CXCL6 (granulocyte chemotactic protein-2): a novel chemokine involved in the innate immune response of the amniotic cavity
10.1111/j.1600-0897.2008.00620.x · 2008 · External reference
Wound exudate CXCL6: a potential biomarker for wound healing of diabetic foot ulcers
10.2217/bmm-2018-0339 · 2019 · External reference
CXCL6: a potential therapeutic target for inflammation and cancer
10.1007/s10238-023-01152-8 · 2023 · External reference
Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis
10.1016/j.canlet.2010.12.013 · 2011 · External reference
CXCL6 promotes non-small cell lung cancer cell survival and metastasis via down-regulation of miR-515-5p
10.1016/j.biopha.2017.11.004 · 2018 · External reference
CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway
10.1002/jcp.30236 · 2021 · External reference
Increased expression of CXCL6 in secretory cells drives fibroblast collagen synthesis and is associated with increased mortality in idiopathic pulmonary fibrosis
10.1183/13993003.00088-2023 · 2024 · External reference
CXCL6 in idiopathic pulmonary fibrosis: a novel mediator in the complex epithelial-mesenchymal crosstalk
10.1183/13993003.01954-2023 · 2024 · External reference
Neutrophil elastase: alpha-1-proteinase inhibitor complex in serum and bronchoalveolar lavage fluid in patients with pulmonary fibrosis
10.1183/09031936.98.11010120 · 1998 · External reference
Neutrophil levels correlate with quantitative extent and progression of fibrosis in IPF: results of a single-Centre cohort study
2023 · External reference
Leukotrienes mediate murine bronchopulmonary Hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine Interleukin-13
10.1165/rcmb.2002-0032oc · 2003 · External reference
Biyuan Tongqiao granules ameliorates acute lung injury induced by lipopolysaccharides by PI3K/AKT/mTOR signaling pathway
10.1016/j.jep.2025.120232 · 2025 · External reference
Deranged fatty acid composition causes pulmonary fibrosis in Elovl6-deficient mice
10.1038/ncomms3563 · 2013 · External reference
Simple method of estimating severity of pulmonary fibrosis on a numerical scale
10.1136/jcp.41.4.467 · 1988 · External reference
CXCL6 antibody neutralization prevents lung inflammation and fibrosis in mice in the bleomycin model
10.1189/jlb.0313140 · 2013 · External reference
Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone
10.1007/s00262-025-03946-z · 2025 · External reference
Pirfenidone regulates LPS mediated activation of neutrophils
10.1038/s41598-020-76271-3 · 2020 · External reference
Disease modification and symptom relief in osteoarthritis using a mutated GCP-2/CXCL6 chemokine
10.15252/emmm.202216218 · 2023 · External reference
CXCL6 reshapes lipid metabolism and induces neutrophil extracellular trap formation in cholangiocarcinoma progression and immunotherapy resistance
2025 · External reference
The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis
10.1016/j.immuni.2021.06.008 · 2021 · External reference
Biomarker signatures for progressive idiopathic pulmonary fibrosis
10.1183/13993003.01181-2021 · 2022 · External reference
Identification and validation of chemokine system-related genes in idiopathic pulmonary fibrosis
2023 · External reference
Diverse injury pathways induce alveolar epithelial cell CCL2/12, which promotes lung fibrosis
10.1165/rcmb.2019-0297oc · 2020 · External reference
Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis
10.1164/rccm.200808-1201oc · 2009 · External reference
C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis
10.1164/rccm.201309-1592oc · 2014 · External reference
Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis
10.1378/chest.07-1948 · 2008 · External reference
Neutrophil dynamics in pulmonary fibrosis: pathophysiological and therapeutic perspectives
2024 · External reference
Sequential nanoparticle therapy targeting neutrophil hyperactivation to prevent neutrophil-induced pulmonary fibrosis
10.1186/s12951-025-03421-y · 2025 · External reference
Neutrophils modulate fibrogenesis in chronic pulmonary diseases
10.3389/fmed.2021.616200 · 2021 · External reference
Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential
10.1002/path.5221 · 2019 · External reference
RIPK1 inhibitor ameliorates pulmonary injury by modulating the function of neutrophils and vascular endothelial cells
10.1038/s41420-024-01921-8 · 2024 · External reference
Neutrophil extracellular traps and pulmonary fibrosis: an update
10.1186/s12950-023-00329-y · 2023 · External reference
IL-1 pathways in inflammation and human diseases
10.1038/nrrheum.2010.4 · 2010 · External reference
The activation of IL-1-induced enhancers depends on TAK1 kinase activity and NF-κB p65
10.1016/j.celrep.2015.01.001 · 2015 · External reference
Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit
10.1128/mcb.19.7.4798 · 1999 · External reference
IL-1β-activated PI3K/AKT and MEK/ERK pathways coordinately promote induction of partial epithelial-mesenchymal transition
10.1186/s12964-024-01775-8 · 2024 · External reference
IL-23 and IL-1β drive human Th17 cell differentiation and metabolic reprogramming in absence of CD28 Costimulation
10.1016/j.celrep.2018.02.044 · 2018 · External reference
Erythropoietin mediates re-programming of endotoxin-tolerant macrophages through PI3K/AKT signaling and protects mice against secondary infection
2022 · External reference
Reactive oxygen species-evoked endoplasmic reticulum stress mediates 1-nitropyrene-induced epithelial-mesenchymal transition and pulmonary fibrosis
10.1016/j.envpol.2021.117134 · 2021 · External reference
The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis
10.1186/1465-9921-6-11 · 2005 · External reference
Co-Mn complex oxide nanoparticles as potential reactive oxygen species scavenging agents for pulmonary fibrosis treatment
10.3390/molecules29215106 · 2024 · External reference
Targeted metabolic reprogramming with lactate-scavenging CeO2@PLP nanoparticles attenuates pulmonary fibrosis via dual modulation of macrophage polarization and fibroblast activation
10.1016/j.matdes.2025.115072 · 2025 · External reference
CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway
10.1002/jcp.30236 · ExternalCitation · doi-reference
Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential
10.1002/path.5221 · ExternalCitation · doi-reference
Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone
10.1007/s00262-025-03946-z · ExternalCitation · doi-reference
CXCL6: a potential therapeutic target for inflammation and cancer
10.1007/s10238-023-01152-8 · ExternalCitation · doi-reference
CXCL6 promotes non-small cell lung cancer cell survival and metastasis via down-regulation of miR-515-5p
10.1016/j.biopha.2017.11.004 · ExternalCitation · doi-reference
Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis
10.1016/j.canlet.2010.12.013 · ExternalCitation · doi-reference
The activation of IL-1-induced enhancers depends on TAK1 kinase activity and NF-κB p65
10.1016/j.celrep.2015.01.001 · ExternalCitation · doi-reference
IL-23 and IL-1β drive human Th17 cell differentiation and metabolic reprogramming in absence of CD28 Costimulation
10.1016/j.celrep.2018.02.044 · ExternalCitation · doi-reference
Precision medicine advances in idiopathic pulmonary fibrosis
10.1016/j.ebiom.2023.104766 · ExternalCitation · doi-reference
Reactive oxygen species-evoked endoplasmic reticulum stress mediates 1-nitropyrene-induced epithelial-mesenchymal transition and pulmonary fibrosis
10.1016/j.envpol.2021.117134 · ExternalCitation · doi-reference
The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis
10.1016/j.immuni.2021.06.008 · ExternalCitation · doi-reference
Biyuan Tongqiao granules ameliorates acute lung injury induced by lipopolysaccharides by PI3K/AKT/mTOR signaling pathway
10.1016/j.jep.2025.120232 · ExternalCitation · doi-reference
Targeted metabolic reprogramming with lactate-scavenging CeO2@PLP nanoparticles attenuates pulmonary fibrosis via dual modulation of macrophage polarization and fibroblast activation
10.1016/j.matdes.2025.115072 · ExternalCitation · doi-reference
Interstitial lung diseases
10.1016/s0140-6736(22)01052-2 · ExternalCitation · doi-reference
Deranged fatty acid composition causes pulmonary fibrosis in Elovl6-deficient mice
10.1038/ncomms3563 · ExternalCitation · doi-reference
IL-1 pathways in inflammation and human diseases
10.1038/nrrheum.2010.4 · ExternalCitation · doi-reference
RIPK1 inhibitor ameliorates pulmonary injury by modulating the function of neutrophils and vascular endothelial cells
10.1038/s41420-024-01921-8 · ExternalCitation · doi-reference
Histological signatures map anti-fibrotic factors in mouse and human lungs
10.1038/s41586-025-08727-3 · ExternalCitation · doi-reference
Pirfenidone regulates LPS mediated activation of neutrophils
10.1038/s41598-020-76271-3 · ExternalCitation · doi-reference
Efficacy and safety of Nintedanib in idiopathic pulmonary fibrosis
10.1056/nejmoa1402584 · ExternalCitation · doi-reference
CXCL6 (granulocyte chemotactic protein-2): a novel chemokine involved in the innate immune response of the amniotic cavity
10.1111/j.1600-0897.2008.00620.x · ExternalCitation · doi-reference
Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit
10.1128/mcb.19.7.4798 · ExternalCitation · doi-reference
Simple method of estimating severity of pulmonary fibrosis on a numerical scale
10.1136/jcp.41.4.467 · ExternalCitation · doi-reference
Pathogenic mechanisms underlying idiopathic pulmonary fibrosis
10.1146/annurev-pathol-042320-030240 · ExternalCitation · doi-reference
Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis
10.1164/rccm.200808-1201oc · ExternalCitation · doi-reference
C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis
10.1164/rccm.201309-1592oc · ExternalCitation · doi-reference
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline
10.1164/rccm.202202-0399st · ExternalCitation · doi-reference
Leukotrienes mediate murine bronchopulmonary Hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine Interleukin-13
10.1165/rcmb.2002-0032oc · ExternalCitation · doi-reference
Diverse injury pathways induce alveolar epithelial cell CCL2/12, which promotes lung fibrosis
10.1165/rcmb.2019-0297oc · ExternalCitation · doi-reference
Neutrophil elastase: alpha-1-proteinase inhibitor complex in serum and bronchoalveolar lavage fluid in patients with pulmonary fibrosis
10.1183/09031936.98.11010120 · ExternalCitation · doi-reference
Increased expression of CXCL6 in secretory cells drives fibroblast collagen synthesis and is associated with increased mortality in idiopathic pulmonary fibrosis
10.1183/13993003.00088-2023 · ExternalCitation · doi-reference
Biomarker signatures for progressive idiopathic pulmonary fibrosis
10.1183/13993003.01181-2021 · ExternalCitation · doi-reference
CXCL6 in idiopathic pulmonary fibrosis: a novel mediator in the complex epithelial-mesenchymal crosstalk
10.1183/13993003.01954-2023 · ExternalCitation · doi-reference
Pirfenidone in idiopathic pulmonary fibrosis: hitting two birds with one stone?
10.1183/13993003.02224-2024 · ExternalCitation · doi-reference
The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis
10.1186/1465-9921-6-11 · ExternalCitation · doi-reference
Neutrophil extracellular traps and pulmonary fibrosis: an update
10.1186/s12950-023-00329-y · ExternalCitation · doi-reference
Sequential nanoparticle therapy targeting neutrophil hyperactivation to prevent neutrophil-induced pulmonary fibrosis
10.1186/s12951-025-03421-y · ExternalCitation · doi-reference
IL-1β-activated PI3K/AKT and MEK/ERK pathways coordinately promote induction of partial epithelial-mesenchymal transition
10.1186/s12964-024-01775-8 · ExternalCitation · doi-reference
CXCL6 antibody neutralization prevents lung inflammation and fibrosis in mice in the bleomycin model
10.1189/jlb.0313140 · ExternalCitation · doi-reference
Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis
10.1378/chest.07-1948 · ExternalCitation · doi-reference
Idiopathic pulmonary fibrosis: the inflammation hypothesis revisited
10.1378/chest.124.4.1187 · ExternalCitation · doi-reference
Disease modification and symptom relief in osteoarthritis using a mutated GCP-2/CXCL6 chemokine
10.15252/emmm.202216218 · ExternalCitation · doi-reference
Wound exudate CXCL6: a potential biomarker for wound healing of diabetic foot ulcers
10.2217/bmm-2018-0339 · ExternalCitation · doi-reference
Neutrophils modulate fibrogenesis in chronic pulmonary diseases
10.3389/fmed.2021.616200 · ExternalCitation · doi-reference
The chemokine system as a key regulator of pulmonary fibrosis: converging pathways in human idiopathic pulmonary fibrosis (IPF) and the bleomycin-induced lung fibrosis model in mice
10.3390/cells13242058 · ExternalCitation · doi-reference
Co-Mn complex oxide nanoparticles as potential reactive oxygen species scavenging agents for pulmonary fibrosis treatment
10.3390/molecules29215106 · ExternalCitation · doi-reference
